We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+23.45%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.68B
AUM Growth
+$331M
Cap. Flow
+$76.5M
Cap. Flow %
4.56%
Top 10 Hldgs %
63.28%
Holding
89
New
21
Increased
18
Reduced
12
Closed
21

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$44.6M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.9M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$12.3M
4
AMGN icon
Amgen
AMGN
+$12.2M
5
MGNX icon
MacroGenics
MGNX
+$10.6M

Top Sells

Rank Stock Value
1
NXTC icon
NextCure
NXTC
+$23.5M
2
MRK icon
Merck
MRK
+$15.8M
3
LLY icon
Eli Lilly
LLY
+$15.8M
4
INSM icon
Insmed
INSM
+$11.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.46M

Sector Composition

Rank Sector Weight
1 Healthcare 91.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SUPN icon
76
Supernus Pharmaceuticals
SUPN
$2.7B
– –
-330,295
Closed -$6.88M
SVRA icon
77
Savara
SVRA
$1.08B
– –
-375,591
Closed -$409K
ZYME icon
78
Zymeworks
ZYME
$1.62B
– –
-151,902
Closed -$7.08M
QTTB icon
79
Q32 Bio
QTTB
$435M
– –
-13,223
Closed -$2.55M
MRNS
80
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-175,000
Closed -$8.99M
RETA
81
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-60,000
Closed -$5.84M
AGTC
82
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-825,071
Closed -$4.01M
ETTX
83
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
– –
-1,012,408
Closed -$2.06M
CHMA
84
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-1,047,354
Closed -$4.5M
MYOK
85
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-48,998
Closed -$6.68M
1 2 3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2020 Portfolio in Review

As of Q4 2020, Sofinnova Investments held 89 positions worth $1.68B, up 25% from $1.35B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sofinnova Investments deployed $76.5M of net new capital in Q4 2020, opening 21 new positions and adding to 18 existing holdings. Its largest new stake was AstraZeneca: 421,300 shares worth $42.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier.

On the sell side, the largest reduction was Eli Lilly, an estimated $15.8M trimmed.

  • Sofinnova Investments's largest Q4 2020 buy was AstraZeneca: 421,300 shares worth $42.1M.
  • Sofinnova Investments added most to Jazz Pharmaceuticals in Q4 2020, an estimated $12.3M increase.
  • Sofinnova Investments's biggest Q4 2020 reduction was Eli Lilly, cutting an estimated $15.8M.
  • Sofinnova Investments fully exited NextCure in Q4 2020, selling an estimated $23.5M.
  • Sofinnova Investments's ten largest holdings make up 63% of its $1.68B portfolio in Q4 2020.
  • Sofinnova Investments opened 21 new positions and closed 21 in Q4 2020.
  • Sofinnova Investments's portfolio value rose 25% quarter-over-quarter to $1.68B.

Based on Sofinnova Investments's 13F filing for Q4 2020, filed 16 Feb 2021.